Glaukos Corporation
GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's producā¦ read more
Healthcare
Medical Devices
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$97.02
Price-0.79%
-$0.77
1Y
Price
Market Cap
$5.635b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-90.6%
EBITDA Margin-93.4%
Net Profit Margin+2.8%
Free Cash Flow Margin-90.6%
EBITDA Margin-93.4%
Net Profit Margin+2.8%
Free Cash Flow MarginRevenue
$507.442m
+32.3%
1y CAGR+21.8%
3y CAGR+15.4%
5y CAGREarnings
-$187.691m
-28.2%
1y CAGR-24.2%
3y CAGR-43.2%
5y CAGREPS
-$3.28
-17.7%
1y CAGR-16.8%
3y CAGR-36.4%
5y CAGRBook Value
$656.155m
$893.487m
Assets$237.332m
Liabilities$139.643m
DebtDebt to Assets
15.6%
-0.9x
Debt to EBITDAFree Cash Flow
-$54.006m
+66.8%
1y CAGR+19.0%
3y CAGR-29.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company